Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Recruiting · NCT06467617 · Registry updated 2024-12-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2024-12-16 | NCT06467617 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Chest Hospital, Capital Medical University | 11 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Chest Hospital | Beijing | China | 3 |